Flavone acetic acid (FAA) was incubated for 1 to 48 hr with 3 established human colon cancer cell lines endowed with distinct degrees of phenotypic properties. All 3 lines responded to FAA in almost identical fashion; when incubated with the drug for only 1 hr, an initial decrease in survival was ob
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice
โ Scribed by Thomas H. Corbett; Marie-Christine Bissery; Antoinette Wozniak; Jacqueline Plowman; Lisa Polin; Efstathios Tapazoglou; Julia Dieckman; Frederick Valeriote
- Publisher
- Springer US
- Year
- 1986
- Tongue
- English
- Weight
- 1001 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
โฆ Synopsis
Flavone acetic acid (FAA) is a new antitumor agent that has recently entered Phase I clinical trials. In preclinical studies, we have found that FAA was broadly active against a variety of transplantable solid tumors of mice (colon # 51, #07, # 10, #26; pancreatic ductal adenocarcinomas #02 and #03; mammary adenocarcinoma # 16/C/Adr; M5076 reticulum cell sarcoma and Glasgow's osteosarcoma). FAA was curative for colon adenocarcinoma # 10 and pancreatic ductal adenocarcinoma # 03. Thus, for the first time an agent has been identified with very broad, perhaps nearly universal solid tumor activity. FAA was also found to be orally active and stable in solution at 37~ for 48 h. FAA was selectively cytotoxic in vitro for solid tumors over leukemias L1210 and P388 (in a soft-agar colony formation assay), thus correlating cellular selectivity in vitro with in vivo antitumor activity. The finding that FAA was active in vitro, established that the agent did not need metabolism (activation) outside the tumor cell. The main drawback of FAA was an unusual 'threshold' behavior in which only a narrow range of doses were active and splitting the dose markedly decreased activity.
๐ SIMILAR VOLUMES
Batracylin (NSC 320846) is a water insoluble, solid tumor active compound discovered by the Development Therapeutics Program of the National Cancer Institute (NCI). In vivo, the NCI found this compound to be highly active [median treated tumor mass/median control tumor mass (T/C) = 0 to 20%] both or